You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. N/A

    SBC: US NANOCORP, INC.            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health
  2. N/A

    SBC: VERACHEM LLC            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health
  3. N/A

    SBC: Zebra Pharmaceuticals, Inc.            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health
  4. N/A

    SBC: Zebra Pharmaceuticals, Inc.            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health
  5. A P. falciparum MSP1 p42/QS-21 malaria vaccine

    SBC: Agenus Inc.            Topic: N/A

    DESCRIPTION: (Adapted from Applicant's Abstract) Malaria is a disease which affects more than 300 million people each year and is fatal for 1.5 million. The overall objective of this STTR Phase I project is to produce a cGMP malaria vaccine consisting of the 42 kDa C-terminal polypeptide of P. falciparum merozoite surface protein-1 (MSP1.42) to be formulated with ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  6. NOVEL THERAPEUTIC APPROACH TO PSORIASIS

    SBC: BETHESDA PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (Applicant's abstract): Psoriasis is a common, inflammatory disease of the skin characterized by hyper-proliferation of keratinocytes. A variety of antipsoriatic therapies are available, however, due to problems with side effects and variability in clinical response, intense clinical and commercial interest remains in the development of new treatments. Thiaz ...

    STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health
  7. NOVEL THERAPEUTIC APPROACH TO PSORIASIS

    SBC: BETHESDA PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (Applicant's abstract): Psoriasis is a common, inflammatory disease of the skin characterized by hyper-proliferation of keratinocytes. A variety of antipsoriatic therapies are available, however, due to problems with side effects and variability in clinical response, intense clinical and commercial interest remains in the development of new treatments. Thiaz ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  8. Biomaterials for Orbit Reconstruction

    SBC: BIOMIMESYS, INC.            Topic: N/A

    DESCRIPTION (Verbatim from Applicant): We will develop biomimetic materials for repair and orthoplasty of the orbit and surrounding bony structures. These scaffolds will incorporate a cell binding peptide related to collagen which will allow them to serve as collagen-like anchorages for cells. These Collagen Surrogate Matrices (CSM) will facilitate haptotactic migrati ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  9. Neuroprotective Drugs for Spinal Cord Injury

    SBC: Biostream Therapeutics, Inc.            Topic: N/A

    DESCRIPTION: (Adapted from the Applicant's Abstract) Traumatic spinal cord injury (SCI) leads to permanent loss of motor function and control of function below the level of the injury. A significant portion of the loss is due to secondary factors rather than the initial trauma. These factors include increased extracellular concentrations of glutamate which ha ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
  10. Neuroadaptive effects after chronic CTDP 31446 treatment

    SBC: Biostream Therapeutics, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Cocaine abuse remains a grave concern for the American, and increasingly the world, population. As no current therapeutic agents are available to assist cocaine addicts in achieving and maintaining abstinence it is important that new pharmacotherapies be developed. One important question not usually addressed in the development ...

    STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government